DK0882132T3 - Et kombineret humant cytomegalovirus-antigen og anvendelse heraf - Google Patents

Et kombineret humant cytomegalovirus-antigen og anvendelse heraf

Info

Publication number: DK0882132T3
Authority: DK; Denmark
Prior art keywords: human cytomegalovirus; hcmv; combined human; cytomegalovirus antigen; specific antibodies
Prior art date: 1996-02-22

Application number

DK97905078T

Other languages

English (en)

Inventor

Catharina Anna Bruggeman

Cornelis Vink

Frans Stals

Albert Ramon

Original Assignee

Univ Maastricht

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-22

Filing date

1997-02-20

Publication date

2006-03-06

1997-02-20 Application filed by Univ Maastricht filed Critical Univ Maastricht

2006-03-06 Application granted granted Critical

2006-03-06 Publication of DK0882132T3 publication Critical patent/DK0882132T3/da

Links

241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 6
239000000427 antigen Substances 0.000 title abstract 2
102000036639 antigens Human genes 0.000 title abstract 2
108091007433 antigens Proteins 0.000 title abstract 2
238000003556 assay Methods 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK97905078T 1996-02-22 1997-02-20 Et kombineret humant cytomegalovirus-antigen og anvendelse heraf DK0882132T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/605,541 US5800981A (en)	1996-02-22	1996-02-22	Human cytomegalovirus antigen and its use

Publications (1)

Publication Number	Publication Date
DK0882132T3 true DK0882132T3 (da)	2006-03-06

Family

ID=24424094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97905078T DK0882132T3 (da)	1996-02-22	1997-02-20	Et kombineret humant cytomegalovirus-antigen og anvendelse heraf

Country Status (9)

Country	Link
US (1)	US5800981A (da)
EP (1)	EP0882132B1 (da)
JP (1)	JP2001517072A (da)
AT (1)	ATE307207T1 (da)
AU (1)	AU732254B2 (da)
DE (1)	DE69734387T2 (da)
DK (1)	DK0882132T3 (da)
ES (1)	ES2251016T3 (da)
WO (1)	WO1997031117A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757169B1 (fr) *	1996-12-13	1999-03-05	Inst Nat Sante Rech Med	Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
DE19910044A1 (de) *	1999-03-08	2000-09-14	Bodo Plachter	Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1057895A1 (de) *	1999-06-04	2000-12-06	Lohmann Animal Health GmbH & Co. KG	Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
US6569616B1 (en) *	1999-07-29	2003-05-27	Wisconsin Alumni Research Foundation	Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
RU2218408C2 (ru) *	2001-11-05	2003-12-10	Государственный научный центр вирусологии и биотехнологии "Вектор"	РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pUL83HCMV, ОБЕСПЕЧИВАЮЩАЯ ЭКСПРЕССИЮ В КЛЕТКАХ БАКТЕРИИ Escherichia coli РЕКОМБИНАНТНОГО БЕЛКА, СОДЕРЖАЩЕГО ИММУНОДОМИНАНТНУЮ ЧАСТЬ ФОСФОПРОТЕИНА pp65 HCMV И ФРАГМЕНТ β-ГАЛАКТОЗИДАЗЫ
WO2004058166A2 (en) *	2002-12-23	2004-07-15	Vical Incorporated	Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004076645A2 (en) *	2003-02-27	2004-09-10	University Of Massachusetts	Compositions and methods for cytomegalovirus treatment
CA2623694A1 (en) *	2005-09-27	2007-04-05	Oncalis Ag	Genetic selection system to identify proteases, protease substrates and protease inhibitors
GB0700133D0 (en)	2007-01-04	2007-02-14	Humabs Llc	Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en)	2007-01-04	2011-05-24	Humabs, LLC.	Human cytomegalovirus neutralising antibodies and use thereof
PE20141398A1 (es)	2008-07-16	2014-10-18	Inst Research In Biomedicine	Anticuerpos neutralizantes de citomegalovirus humano
AU2010334809C1 (en)	2009-12-23	2015-02-26	Agenus Inc.	Binding members for human cytomegalovirus
US10611800B2 (en)	2016-03-11	2020-04-07	Pfizer Inc.	Human cytomegalovirus gB polypeptide
US11629172B2 (en)	2018-12-21	2023-04-18	Pfizer Inc.	Human cytomegalovirus gB polypeptide
TWI871709B (zh)	2020-06-21	2025-02-01	美商輝瑞股份有限公司	人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1266740B1 (it) *	1994-07-01	1997-01-14	Maria Paola Landini	Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
DE4426453C1 (de) *	1994-07-26	1995-11-02	Biotest Ag	Rekombinant hergestellte Fusionsproteine des Cytomegalievirus und diese enthaltende diagnostische Testkits

1996
- 1996-02-22 US US08/605,541 patent/US5800981A/en not_active Expired - Lifetime
1997
- 1997-02-20 WO PCT/EP1997/000865 patent/WO1997031117A2/en not_active Ceased
- 1997-02-20 AU AU18763/97A patent/AU732254B2/en not_active Ceased
- 1997-02-20 AT AT97905078T patent/ATE307207T1/de not_active IP Right Cessation
- 1997-02-20 EP EP97905078A patent/EP0882132B1/en not_active Expired - Lifetime
- 1997-02-20 JP JP52981597A patent/JP2001517072A/ja active Pending
- 1997-02-20 ES ES97905078T patent/ES2251016T3/es not_active Expired - Lifetime
- 1997-02-20 DE DE69734387T patent/DE69734387T2/de not_active Expired - Lifetime
- 1997-02-20 DK DK97905078T patent/DK0882132T3/da active

Also Published As

Publication number	Publication date
AU732254B2 (en)	2001-04-12
JP2001517072A (ja)	2001-10-02
ES2251016T3 (es)	2006-04-16
EP0882132B1 (en)	2005-10-19
WO1997031117A2 (en)	1997-08-28
US5800981A (en)	1998-09-01
DE69734387T2 (de)	2006-07-06
AU1876397A (en)	1997-09-10
DE69734387D1 (de)	2006-03-02
ATE307207T1 (de)	2005-11-15
EP0882132A2 (en)	1998-12-09
WO1997031117A3 (en)	1997-10-02

Similar Documents

Publication	Publication Date	Title
WO1997031117A3 (en)	1997-10-02	A human cytomegalovirus combined antigen and its use
WO2003048337A3 (en)	2004-08-12	Antibody to latent membrane proteins and uses thereof
EA199700272A1 (ru)	1998-04-30	Вакцины, содержащие сапонин и стерин
EP0344940A3 (en)	1991-11-13	Antibodies to human papillomavirus latent proteins, diagnostic systems and methods
NO970221D0 (no)	1997-01-17	Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
NO991449D0 (no)	1999-03-25	Antistoff mot human parathormon-relaterte peptider
EP0832105A4 (en)	2002-02-06	IMMUNOGENIC PEPTIDES OF PROSTATE-SPECIFIC ANTIGENS
DE69734882D1 (de)	2006-01-19	Dna immunisierung gegen chlamydia infektion
FI910497A0 (fi)	1991-02-01	Nytt virus vid infektioes bursalsjukdom.
DE69629674D1 (de)	2003-10-02	Dns-sequenzen des humanen cytomegaloviruses
HUP9801223A3 (en)	2000-12-28	Method for enhancing the antibody response to specific antigens with interleukin-10
FI944225L (fi)	1995-03-15	Diagnostisia reagensseja EBV:n vasta-aineiden detektoimiseksi
DE69504959D1 (de)	1998-10-29	Humanisierte monoklonale antikörper gegen humanes interleukin - 4
AU2133292A (en)	1993-03-04	Hcmv-specific peptides, agents therefor and the use thereof
WO1995016040A3 (en)	1995-08-17	Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
EP0683675A4 (en)	1997-05-21	HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
DK364286A (da)	1987-03-20	Varicella-zoster virus (vzv) ga, gb og gc glycoproteiner i renset, ikke-denatureret, serologisk aktiv form og fremgangsmaade til proevning for tilstedevaerelsen af antistoffer over for disse
AU3245000A (en)	2000-09-14	Compounds and methods for the detection and prevention of (t. cruzi) infection
CA2246802A1 (en)	1997-08-28	A human cytomegalovirus combined antigen and its use
KR950702244A (ko)	1995-06-19	백신으로서의 즉석 초기 hsv-2 비루스 단백질 icp27(immediatie early hsv-2 viral protein icp27 as vaccine)
AU635124B2 (en)	1993-03-11	Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
FR2737209B1 (fr)	1997-09-19	Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c
AU646275C (en)	1995-01-19	Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
AP9300556A0 (en)	1993-10-31	Peptides,analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
EP1071325A4 (en)	2004-12-22	COMPOSITIONS AND METHODS FOR ANTI-SPECIFIC Vaccination